Rather, characteristic features arising from mutations include inactivation of the tumor suppressors TP53 (~85% of cases) and RB1 (~57% of cases), reduction in activity of NOTCH (~14%), altered function of the TP53-related protein TP73 (~13%), and amplification causing overexpression of MYC (~7%) [12]. The gene discussed is TP53; the disease is neoplasm.